These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15725424)

  • 1. Extrapyramidal symptoms in unmedicated schizophrenia.
    McCreadie RG; Srinivasan TN; Padmavati R; Thara R
    J Psychiatr Res; 2005 May; 39(3):261-6. PubMed ID: 15725424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychopathology in never-treated schizophrenia.
    Tirupati SN; Padmavati R; Thara R; McCreadie RG
    Compr Psychiatry; 2006; 47(1):1-6. PubMed ID: 16324896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
    Honer WG; Kopala LC; Rabinowitz J
    J Psychopharmacol; 2005 May; 19(3):277-85. PubMed ID: 15888513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia.
    Zhornitsky S; Stip E; Pampoulova T; Rizkallah E; Lipp O; Bentaleb LA; Chiasson JP; Potvin S
    Mov Disord; 2010 Oct; 25(13):2188-94. PubMed ID: 20669315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Motor disturbances in psychiatric patients].
    Rüther E
    Psychiatr Prax; 2005 Apr; 32 Suppl 1():S3-6. PubMed ID: 15818515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders.
    Ganzini L; Casey DE; Hoffman WF; McCall AL
    Arch Intern Med; 1993 Jun; 153(12):1469-75. PubMed ID: 8512437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions.
    Dean CE; Kuskowski MA; Caligiuri MP
    J Clin Psychopharmacol; 2006 Dec; 26(6):560-5. PubMed ID: 17110811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Community dysfunction in schizophrenia: rate-limiting factors.
    Bozikas VP; Kosmidis MH; Kafantari A; Gamvrula K; Vasiliadou E; Petrikis P; Fokas K; Karavatos A
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):463-70. PubMed ID: 16442195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients.
    Chatterjee A; Chakos M; Koreen A; Geisler S; Sheitman B; Woerner M; Kane JM; Alvir J; Lieberman JA
    Am J Psychiatry; 1995 Dec; 152(12):1724-9. PubMed ID: 8526237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychosis in elderly patients: classification and pharmacotherapy.
    Mintzer J; Targum SD
    J Geriatr Psychiatry Neurol; 2003 Dec; 16(4):199-206. PubMed ID: 14653427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors, pre-morbid functioning and episode correlates of neurological soft signs in drug-naive patients with schizophrenia-spectrum disorders.
    Peralta V; de Jalón EG; Campos MS; Basterra V; Sanchez-Torres A; Cuesta MJ
    Psychol Med; 2011 Jun; 41(6):1279-89. PubMed ID: 20860873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neurological soft signs in schizophrenic patients and their nonaffected siblings].
    Mechri A; Slama H; Bourdel MC; Chebel S; Mandhouj O; Krebs MO; Gaha L
    Encephale; 2008 Oct; 34(5):483-9. PubMed ID: 19068337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of extrapyramidal symptoms to age at onset and drug treatment in middle-aged and elderly schizophrenic patients.
    Srinivasan TN; Thara R; Padmavathi R; McCreadie RG
    Schizophr Res; 2001 Jan; 47(1):69-75. PubMed ID: 11163546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Motor behavior abnormalities in drug-naïve patients with schizophrenia spectrum disorders.
    Peralta V; Campos MS; De Jalón EG; Cuesta MJ
    Mov Disord; 2010 Jun; 25(8):1068-76. PubMed ID: 20222137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia.
    Damier P; Thobois S; Witjas T; Cuny E; Derost P; Raoul S; Mertens P; Peragut JC; Lemaire JJ; Burbaud P; Nguyen JM; Llorca PM; Rascol O;
    Arch Gen Psychiatry; 2007 Feb; 64(2):170-6. PubMed ID: 17283284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motoric neurological soft signs and psychopathological symptoms in schizophrenic psychoses.
    Jahn T; Hubmann W; Karr M; Mohr F; Schlenker R; Heidenreich T; Cohen R; Schröder J
    Psychiatry Res; 2006 Jun; 142(2-3):191-9. PubMed ID: 16650902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up.
    McCreadie RG; Padmavati R; Thara R; Srinivasan TN
    Br J Psychiatry; 2002 Aug; 181():135-7. PubMed ID: 12151284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia.
    Fervaha G; Agid O; Takeuchi H; Lee J; Foussias G; Zakzanis KK; Graff-Guerrero A; Remington G
    Schizophr Res; 2015 Feb; 161(2-3):351-6. PubMed ID: 25471015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial.
    Lerner V; Miodownik C; Gibel A; Kovalyonok E; Shleifer T; Goodman AB; Ritsner MS
    Clin Neuropharmacol; 2008; 31(1):25-33. PubMed ID: 18303488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.